tumor treating: Live & Latest News Updates : Vimarsana.com

Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Novocure today announced 20 presentations on Tumor Treating Fields therapy will be delivered at the American Association for Cancer Research Annual Meeting 2024, to be held April 5 to 10 in San...

From Patient To Million Dollar Woman: The Terrible Inequity Of Brain Cancer

OurBrainBank is putting a spotlight on the devastating inequities that exist for those with GBM to spark debate and force more to be done for those who need it.

Novocure to Report First Quarter 2024 Financial Results

ROOT, Switzerland, April 01, 2024--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference call by phone, use the following conference call registration link and dial-in d

Novocure: METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Novocure: INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

ROOT, Switzerland--(BUSINESS WIRE)--Mar 11, 2024--

NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the NovoCure Q4 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug...

NovoCure (NVCR) Q4 2023 Earnings Call Transcript

NVCR earnings call for the period ending December 31, 2023.